Clinical trials: COVID19 ARDS
Acute Respiratory Distress Syndrome
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Recent COVID 19 pandemic has overwhelmed health services all around the world, and humanity has yet to find a cure or a vaccine for the treatment of patients, mainly the severe ones, who pose a therapeutic challenge to healthcare…
- Trial name
- NCT04390152
- Testing
- Wharton's jelly derived Mesenchymal stem cells.
- Where
- 2 sites in Colombia
- Volunteers
- 6 people
- Sponsor
- BioXcellerator
Acute Respiratory Distress Syndrome, Coronavirus Infection
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04478071
- Testing
- vadadustat
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- The University of Texas Health Science Center, Houston
Coronavirus
Eculizumab (Soliris) in Covid-19 Infected Patients
Covid-19 has spread rapidly throughout the world causing widespread panic, death, and injury. While this virus is the provocateur, it is often the patient's own disproportionate immune response which deals the most devastating…
- Trial name
- SOLID-C19 (NCT04288713)
- Testing
- Eculizumab
- Sponsor
- Hudson Medical
COVID-19, Respiratory Insufficiency
Telmisartan in Respiratory Failure Due to COVID-19
Rationale: The renin-angiotensin-aldosterone system (RAAS) dysregulation may play a central role in the pathophysiology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection associated acute lung injury (ALI)…
- Conditions
- COVID-19, Respiratory Insufficiency, Telmisartan, Respiratory Distress Syndrome, Adult
- Trial name
- STAR-COVID (NCT04510662)
- Testing
- Telmisartan
- Where
- Mexico
- Volunteers
- 66 people
- Sponsor
- Abraham Edgar Gracia-Ramos
Acute Respiratory Distress Syndrome, COVID-19
Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19
With the influx of patients suspected of Covid-19 and the limited number of hospital beds, there is a need for sensitive triage to detect patients at risk of pulmonary complications and therefore requiring hospitalization, but…
- Trial name
- VIRUS (NCT04370249)
- Testing
- pulmonary ultrasound
- Where
- France
- Volunteers
- 313 people
- Sponsor
- Nantes University Hospital
COVID-19
Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies
COVID-19 associated mortality remains high despite the advances in therapeutics such as dexamethasone. The severity of COVID-19 results from direct viral cytotoxicity, and the inflammatory response, which is associated with a…
- Trial name
- EPIC (NCT05182515)
- Testing
- Therapeutic plasma exchange
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier St Anne
ARDS: Acute Respiratory Distress Syndrome, Covid19
Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS
The goal of this observational study is to learn about the effect of steroid therapy in patients with COVID-19 ARDS. The main questions it aims to answer are: Differences between patients with COVID-19 ARDS before and after…
- Trial name
- NCT05933291
- Testing
- steroid
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Peking Union Medical College Hospital
Enteral Nutrition, COVID-19 Acute Respiratory Distress Syndrome
Early Versus Delayed Enteral Nutrition in Critically Ill Adults With COVID-19
The goal of this observational study is to determine the relationship between the nutritional profile of critically ill patients diagnosed with COVID-19 and disease severity, prognosis, and survival, to assess the ability to meet…
- Trial name
- NCT06134674
- Where
- Turkey (Türkiye)
- Volunteers
- 135 people
- Sponsor
- Ankara City Hospital Bilkent
COVID-19
Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial
This is a a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of…
- Trial name
- DART (NCT04482621)
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
COVID-19, Cytokine Storm
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. COVID-19 causes life threatening complications known as Cytokine Release Syndrome or Cytokine Storm and Acute Respiratory Distress…
- Conditions
- COVID-19, Cytokine Storm, Acute Respiratory Distress Syndrome
- Trial name
- CORONA (NCT04378244)
- Testing
- DeltaRex-G
- Sponsor
- Aveni Foundation
COVID-19, ARDS, Human
Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19
Surfactant replacement therapy (SRT) improves oxygenation and survival in NRDS and some infant ARDS. SRT was tried in adult ARDS with conflicting results.
- Trial name
- Caards-1 (NCT04384731)
- Testing
- poractant alfa
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Dr Christophe LENCLUD
COVID-19, ARDS, Human
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
This study consists of two parts. Part A (Phase I): A Phase I Double-blind Randomized Placebo-controlled Study in Healthy Subjects to Assess the Safety, Pharmacokinetics, Pharmacodynamics of MRG-001 Part B (Phase 2): A Phase IIa…
- Conditions
- COVID-19, ARDS, Human, Stem Cells, Regeneration
- Trial name
- NCT04646603
- Testing
- MRG-001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- MedRegen LLC
COVID-19 Pneumonia
Nebulised Heparin in Patients With COVID-19 Pneumonia
While the pandemic continues to incite panic and the guideline recommendations regarding management of COVID continue to change, we have growing evidence that ARDS secondary to Covid-19 is associated with disseminated…
- Trial name
- NCT05255848
- Testing
- Unfractionated heparin
- Where
- Pakistan
- Volunteers
- 180 people
- Sponsor
- Lady Reading Hospital, Pakistan
COVID-19 Infection
Neurological and Neuropsychological Sequelae of COVID-19 Infection
COVID-19 is known to affect the respiratory system but may also have an impact on other organ systems, including the brain. A number of severely ill patients also presents neurological symptoms that may be the result of COVID-19…
- Trial name
- NeNeSCo (NCT04745611)
- Testing
- MRI, Neuropsychological assessment, Questionnaires Patient
- Where
- 3 sites in Netherlands
- Volunteers
- 329 people
- Sponsor
- Maastricht University
Severe Acute Respiratory Syndrome, Respiratory Failure
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
The global pandemic COVID-19 has overwhelmed the medical capacity to accommodate a large surge of patients with acute respiratory distress syndrome (ARDS).
- Conditions
- Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
- Trial name
- NCT04357730
- Testing
- Alteplase 50 MG [Activase]
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Denver Health and Hospital Authority
Covid19
Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in…
- Trial name
- XACT (NCT04640181)
- Testing
- Enoxaparin, Rivaroxaban
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- St. David's HealthCare
SARS-CoV Infection, Acute Respiratory Distress Syndrome
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
A randomized, double blind, multicenter, placebo-controlled, parallel group, fixed dose, phase II study to evaluate the efficacy and safety of glenzocimab in ARDS.
- Conditions
- SARS-CoV Infection, Acute Respiratory Distress Syndrome, COVID-19, ARDS
- Trial name
- GARDEN (NCT04659109)
- Testing
- glenzocimab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Acticor Biotech
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially…
- Trial name
- regARDS (NCT05027815)
- Testing
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jeffrey Bluestone
Covid19, SARS-CoV Infection
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
SARS-CoV-2 is a member of a class of viruses: angiotensin converting enzyme 2 (ACE2)-binding viruses that study calls "ABVs". The World Health Organization (WHO) and others are performing randomized controlled trials (RCTs) of…
- Trial name
- ARBs CORONA II (NCT04606563)
- Testing
- Losartan, Valsartan, Azilsartan
- Where
- 13 sites in Canada, France
- Volunteers
- 341 people
- Sponsor
- University of British Columbia